公开(公告)号：US20170030904A1

公开(公告)日：2017-02-02

申请号：US14883622

申请日：2015-10-15

Applicant: Macau University of Science and Technology

Inventor： Liang LIU ,  Jing-Rong WANG ,  Weina GAO ,  Leefong YAU ,  Hao HUANG ,  Qiong MENG ,  Tiantian TONG ,  Zhi-Hong JIANG

IPC: G01N33/564 ,  B01L3/00

CPC classification number: G01N33/564 ,  B01L3/502715 ,  B01L3/502753 ,  B01L2200/10 ,  B01L2300/069 ,  G01N1/40 ,  G01N1/405 ,  G01N30/08 ,  G01N30/6095 ,  G01N30/7266 ,  G01N33/48 ,  G01N2030/085 ,  G01N2030/8836 ,  G01N2400/10 ,  G01N2440/38 ,  G01N2800/102

Abstract: The present invention discloses a method of determining the presence of autoimmune disease with the use of glycan biomarkers. A method of improving the detection sensitivity of trace glycans from a mixture of glycans and a microfluidic chip therefor are also disclosed.

Abstract translation: 本发明公开了一种使用聚糖生物标志物测定自身免疫性疾病的存在的方法。 还公开了一种从聚糖和微流体芯片的混合物中提高痕量聚糖的检测灵敏度的方法。

公开(公告)号：US20170014375A1

公开(公告)日：2017-01-19

申请号：US14799541

申请日：2015-07-14

Applicant: Macau University of Science and Technology

Inventor： Kam Wai WONG ,  Yuen Kwan LAW ,  Liang LIU ,  Su-Wei XU

IPC: A61K31/352

CPC classification number: A61K31/352

Abstract: The present invention provides a compound of formula (I) as a SERCA inhibitor for treating cancers, a pharmaceutical composition comprising said compound, and methods of using said compound for treating cancers and/or inducing cell death in cells of said cancers. Said cancers include but not limited to cervical, lung, liver, breast, and prostate cancer. Said cancers also include drug-resistant and/or apoptosis-resistant cancers such as isogenic drug-resistant colon cancer. The subject being administered with said compound or the composition comprising thereof can be human or animal subject. Said methods for treating cancers and/or inducing cell death can be a targeting treatment for certain cancers.

Abstract translation: 本发明提供了作为用于治疗癌症的SERCA抑制剂的式（I）化合物，包含所述化合物的药物组合物，以及使用所述化合物治疗癌症和/或诱导所述癌症细胞中的细胞死亡的方法。 所述癌症包括但不限于宫颈癌，肺癌，肝癌，乳腺癌和前列腺癌。 所述癌症还包括耐药性和/或细胞凋亡抵抗性癌症，例如同基因耐药结肠癌。 给予所述化合物或包含其的组合物的受试者可以是人或动物受试者。 用于治疗癌症和/或诱导细胞死亡的所述方法可以是某些癌症的靶向治疗。

公开(公告)号：US20160367546A1

公开(公告)日：2016-12-22

申请号：US14744042

申请日：2015-06-19

Applicant: Macau University of Science and Technology

Inventor： Xiao Jun YAO ,  Lai Han LEUNG ,  Lian Xiang LUO ,  Yan Ling ZHOU ,  Liang LIU

IPC: A61K31/4745

CPC classification number: A61K31/4745

Abstract: The present invention provides a compound that inhibits activity of oncogenic ROS1, a composition comprising said compound. The present invention also provides the use of said composition for treating cancer.

Abstract translation: 本发明提供抑制致癌ROS1活性的化合物，其是包含所述化合物的组合物。 本发明还提供了所述组合物用于治疗癌症的用途。

公开(公告)号：US20160106733A1

公开(公告)日：2016-04-21

申请号：US14985419

申请日：2015-12-31

Applicant: Macau University of Science and Technology

Inventor： Kam Wai WONG ,  Yuen Kwan LAW ,  Liang LIU ,  Jingrong WANG

IPC: A61K31/4748 ,  A61K31/4725

CPC classification number: A61K31/4745 ,  A61K31/4725 ,  A61K31/4748

Abstract: The present invention discloses a method of treating cancer comprising administering an effective amount of an alkaloid, in which the alkaloid is liensinine, isoliensinine, dauricine, cepharanthine, hernandezine or thalidezine and isolated from the traditional Chinese medicinal herbs. The use of the alkaloid in treating neurodegenerative disorder is also disclosed.

公开(公告)号：US20150133492A1

公开(公告)日：2015-05-14

申请号：US14526539

申请日：2014-10-29

Applicant: Macau University of Science and Technology

Inventor： Kam Wai WONG ,  Yuen Kwan LAW ,  Zhi Hong JIANG ,  Liang LIU ,  Wai Kit CHAN ,  Xiao Jun YAO

IPC: A61K31/4725

CPC classification number: A61K31/4725

Abstract: This invention is directed to the use of N-desmethyldauricine, a novel autophagy enhancer, in treating cancers or neurodegenerative conditions.

Abstract translation: 本发明涉及一种新型自噬增强剂N-去甲基牛磺酸在治疗癌症或神经变性疾病中的应用。

公开(公告)号：US20160158163A1

公开(公告)日：2016-06-09

申请号：US14624574

申请日：2015-02-17

Applicant: Macau University of Science and Technology

Inventor： Lai-Han LEUNG ,  Xing-Xing FAN ,  Liang LIU ,  Zebo JIANG

IPC: A61K31/09

CPC classification number: A61K31/09

Abstract: The present invention relates to a method for treating gefitinib-resistant non-small-cell lung cancer (NSCLC) comprising administering an effective amount of a resveratrol analogue, (Z)3,4,5,4′-tetramethoxystilbene (TMS), to a subject in need thereof. The present invention also relates to a method for inducing apoptosis in gefitinib-resistant NSCLC cells comprising contacting the resveratrol analogue to the cells at an effective amount. The present methods are mediated by different signaling pathways connected to cell proliferation and differentiation such as mTOR, JNK, and certain EGFR phosphorylated tyrosine kinase.

Abstract translation: 本发明涉及一种治疗吉非替尼耐药性非小细胞肺癌（NSCLC）的方法，包括将有效量的白藜芦醇类似物（Z）3,4,5,4'-四甲氧基二苯乙烯（TMS）给予 有需要的科目。 本发明还涉及一种诱导吉非替尼耐药NSCLC细胞凋亡的方法，包括以有效量将白藜芦醇类似物与细胞接触。 本发明的方法是通过与细胞增殖和分化相关的不同信号通路介导的，例如mTOR，JNK和某些EGFR磷酸化酪氨酸激酶。

公开(公告)号：US20150031050A1

公开(公告)日：2015-01-29

申请号：US14455951

申请日：2014-08-11

Applicant: Macau University of Science and Technology

Inventor： Liang LIU ,  Ting LI ,  Kam Wai WONG ,  Zhihong JIANG ,  Hua ZHOU

IPC: G01N33/573

CPC classification number: G01N33/573 ,  A61K31/352 ,  A61K31/4188 ,  G01N33/574 ,  G01N2333/91205 ,  G01N2333/91215 ,  G01N2500/04 ,  G01N2800/102 ,  G01N2800/44

Abstract: Uses and applications derived from the discovery of a novel binding site of IKK-β, such as method of screening a therapeutic agent as drug candidate for treating cancer, inflammation, or other diseases/disorders, are provided.

Abstract translation: 提供了从发现IKK-和bgr的新结合位点衍生的用途和应用，例如筛选治疗剂作为治疗癌症，炎症或其它疾病/障碍的候选药物的方法。

公开(公告)号：US20140315867A1

公开(公告)日：2014-10-23

申请号：US14251664

申请日：2014-04-14

Applicant: Macau University of Science and Technology

Inventor： Liang LIU ,  Ting LI ,  Fenggen YAN

IPC: A61K31/353 ,  A61K31/573

CPC classification number: A61K31/353 ,  A61K31/573 ,  A61K2300/00

Abstract: This invention provides a method of preventing and/or treating thymus degeneration comprising administering an effective amount of dihydromyricetin to a subject in need thereof, in which the degeneration is induced by dexamethasone. In one embodiment, the thymus degeneration is induced during the course of treatment of inflammation by dexamethasone.

Abstract translation: 本发明提供了一种预防和/或治疗胸腺变性的方法，包括向有需要的受试者施用有效量的二氢黄芪素，其中由地塞米松引起变性。 在一个实施方案中，在用地塞米松治疗炎症过程中诱导胸腺变性。

公开(公告)号：US20190175553A1

公开(公告)日：2019-06-13

申请号：US16257018

申请日：2019-01-24

Applicant: Macau University of Science and Technology

Inventor： Xiao Jun YAO ,  Lai Han Elaine LEUNG ,  Liang LIU ,  Qian Qian WANG ,  Jia Hui XU ,  Ying LI

IPC: A61K31/4045 ,  A61K45/06 ,  G01N33/574 ,  A61P35/00

Abstract: One embodiment is a method of treating cancer. The method includes administering a therapeutically effective amount of a compound to a patient. The compound is represented by Formula I:

公开(公告)号：US20190175526A1

公开(公告)日：2019-06-13

申请号：US15839883

申请日：2017-12-13

Applicant: Macau University of Science and Technology

Inventor： Xiao Jun YAO ,  Lai Han Elaine LEUNG ,  Liang LIU ,  Jia Hui XU ,  Qian Qian WANG ,  Ying LI

IPC: A61K31/136 ,  A61P35/00 ,  G01N33/574

Abstract: One embodiment relates to a method of treating cancer by administering a compound of Formula I to a patient. Another embodiment relates to a method of treating cancer with overexpressed protein arginine methyltransferases that includes administering to a patient the compound represented by the Formula I: